The sector is quiet and macro seems neutral if not slightly negative but it is early. There is not a lot of news to discuss. I suspect that the trend is to sell biotechs early Monday morning when there is not a major buyout but once the fast money is out, we will get a […]
June 5 Biotech Update
Not much going on except broad and general selling (at least early). It seems like we are in one of those bizarro times where good economic data are bad for the market because it makes rate increases appear more likely and sooner. This action tends to be temporary as expectations for rate hikes can change […]
June 4 Biotech Update
The sector is not doing great but also not significantly pulling back (broader market is lower but also pretty choppy). The large caps appeared weak again and this is still something that we want to follow. The biggest underperformer was CELG and the news after the bell perhaps explains it but that seems like a […]
June 3 Biotech Update
Yesterday was not a great day for the sector with reports of a large sell program in large caps and from what I saw that makes sense. None of the large caps really seemed to rally and every move higher was met with selling. SMID did a little better but we still likely need the […]
June 2 Biotech Update
ASCO is not quite over but my time in ASCO is over and now I am going to spend the next couple of days writing about what I think are both broad and more narrow company specific themes. Keep in mind that the sector usually sells off after ASCO but given the rising importance of […]
Catalyst Watch – Vol. 3, Edition 8 (5/28/15)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: CNAT: Several catalysts […]
May 27 Biotech Update
Yesterday did not get any better and this is certainly not the start to the ASCO run up that the sector would want. That being said there was so little news yesterday, it is not completely surprising that the sector could not break free from the macro worries (Greece and dollar seemed to be the […]
May 26 Biotech Update
What a bad start to the week and by bad I mean slow. The only sound we heard this morning was crickets. Nothing to move the sector in terms of data and nothing on the M&A front (perhaps this is the calm before an ASCO storm). Given the dearth of news and a negative broader […]
13F Analysis of Best Performing Healthcare Hedge Funds (Q1 2015)
13F filings have arrived and it’s like Christmas day for me. I’ve been pouring through the filings, tweeting the interesting ones, and probably annoying everyone on twitter. These filings are a great idea generation tool, a starting place for due diligence, and way to get a peek at the focus of the best minds in […]
May 22 Biotech Update
Yesterday sort of followed the potential new pattern of gaining strength throughout the day but volumes were a little low as we approach the holiday weekend. I suspect today will be even worse, so I will refrain from making any real interpretations of the moves given the lack of volume. 1. There is a lot […]
May 21 Biotech Update
It is a similar start to the trading day with the market sort of flat with the sector a little lower (with notable exceptions which will be discussed below). It was encouraging yesterday that the sector got stronger throughout the day. We were stuck in a pattern with gap higher in the morning and then […]
May 20 Biotech Update
The market was off to a benign start but the sector seemed to take it on the chin (albeit on generally light volume). I am not sure why the selling to start the day as we generally seemed to have some positive news after the bell last night. I do not think it will accelerate […]
May 19 Biotech Update
A mixed start to the morning with some red and green. It seems to me that the market generally wants to move higher but no one seems to have high conviction with that move. I am like everyone else looking for the next shoe to drop and not really trusting the rally. That very well […]
May 18th Biotech Update
The sector seems to be treading water this morning if not slightly outperforming the broader market. There seems to be a tug of war of wanting to be positioned into the potential run ups into ASCO (and EHA) and potential deal flow but the fear of being the last one holding when the sector corrects. […]
Catalyst Watch – Vol. 3, Edition 7 (5/15/15)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: CNAT: Company has […]
May 12 Biotech Update
The sector is being hit this morning, although it is really the market that is weak and taking the sector with it. Yesterday the sector did a good job holding up despite the weak market and hopefully we can extend that relative strength but the early selling seems broad based. Ideally we would like to […]
May 11 Biotech Update
It is a good start to the week which is interesting as we have little news and a lack of M&A. I was curious as to how the sector would respond if we did not have any more M&A announced this Monday and the answer is pretty good. I think that is a bullish signal […]
May 8 Biotech Update
I wish I had more time to write this week but it has been too busy. The sector is obviously doing well and perhaps we have bottomed but at the very least we are set for a relief rally. Perhaps if we can get some additional M&A Monday it will spark a nice rally into […]
May 6 Biotech Update
Well, we finally get another deal and it is pretty telling how the sector reacted. Obviously there is a tailwind but it is not universal and we need to see how it plays out today. There is a tug of war going on in the market and sector and it is amazing that the same […]
Quick update from TRIL Presentation in Toronto
Trillium Therapeutics Inc. (TRIL) – Nasdaq Trillium Therapeutics presented at Bloomburton-2015 Healthcare Investor Conference in Toronto on May 5th, the speaker Dr. Rob Uger, TRIL’s Chief Scientific Officer (CSO) was very informative during the presentation, mentioned that TRIL are looking for a combination therapy with other immunological agents such as Approved cancer antibodies, T cell […]
